INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 78 filers reported holding INOZYME PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 4,494,851 | $18,878,374 | 7.53% |
| CHI Advisors LLC | 1,270,027 | $5,334,112 | 2.11% |
| Samsara BioCapital, LLC | 1,562,500 | $6,562,500 | 2.01% |
| Affinity Asset Advisors, LLC | 1,379,852 | $5,795,378 | 1.63% |
| Sofinnova Investments, Inc. | 4,280,308 | $17,977,294 | 1.13% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,234,907 | $5,186,609 | 0.94% |
| Octagon Capital Advisors LP | 1,300,000 | $5,460,000 | 0.84% |
| NEA Management Company, LLC | 2,437,689 | $10,238,294 | 0.79% |
| Knott David M Jr | 454,008 | $1,907 | 0.73% |
| Rock Springs Capital Management LP | 3,681,174 | $15,460,931 | 0.41% |
| MPM BioImpact LLC | 326,921 | $1,373,068 | 0.37% |
| Eventide Asset Management | 3,125,000 | $13,125,000 | 0.24% |
| SAMLYN CAPITAL, LLC | 3,245,208 | $13,629,873 | 0.22% |
| Overbrook Management Corp | 219,326 | $921,169 | 0.21% |
| Parkman Healthcare Partners LLC | 175,896 | $738,763 | 0.14% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,537,500 | $23,257,500 | 0.05% |
| DENALI ADVISORS LLC | 26,700 | $112,140 | 0.04% |
| GSA CAPITAL PARTNERS LLP | 92,646 | $389 | 0.03% |
| Laurion Capital Management LP | 677,329 | $2,844,782 | 0.02% |
| UBS OCONNOR LLC | 155,305 | $652,281 | 0.02% |
External links
This page lists INOZYME PHARMA INC's shareholders in Q3 2023. To view INOZYME PHARMA INC's shareholder history, click here.